XERS Q3 2022 Earnings — Xeris Biopharma Holdings, Inc. Revenue & Financial Results | Market Cap Arena

XERSXeris Biopharma Holdings, Inc.

$960M

Q3 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$30M+169.4% YoY

Gross Profit

$24M82.3% margin

Operating Income

-$19M-63.2% margin

Net Income

-$22M-73.4% margin

EPS (Diluted)

$-0.16

QoQ Revenue Growth

+17.5%

Cash Flow

Operating Cash Flow

-$18M

Free Cash Flow

-$18M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$303M

Total Liabilities

$248M

Stockholders' Equity

$55M

Cash & Equivalents

$84M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$30M	$11M	+169.4%
Gross Profit	$24M	$8M	+213.1%
Operating Income	-$19M	-$24M	+22.9%
Net Income	-$22M	-$26M	+16.1%

Revenue Segments

Product

$30M69%

Keveyis

$13M31%